QURE Stock Analysis: Buy, Sell, or Hold?
QURE - uniQure N.V.
$46.57
-1.80 (-3.72%)
▼
5d:
-2.92%
30d:
+19.5%
90d:
+92.52%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 29, 2026
0d
Get Alerted When QURE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: QURE shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: QURE shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: QURE is currently trading at $46.57, which is considered extended relative to its 30-day fair value range of $39.63 to $46.70.
Technical Outlook: Technically, QURE is in a strong uptrend. Immediate support is located at $44.22, while resistance sits at $49.84. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: QURE scores 11/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $69.69 (+45.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, QURE is in a strong uptrend. Immediate support is located at $44.22, while resistance sits at $49.84. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: QURE scores 11/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $69.69 (+45.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$39.63 -
$46.70
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
21.1%
Protect Your Profits
Holding QURE? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (11/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 45.3% below Wall St target ($69.69)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$39.63 -
$46.70
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$44.22
Resistance Level
$49.85
Current Trend
Strong Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-18.49
Wall Street Target
$69.70
(+45.3%)
Revenue Growth (YoY)
11.0%
Earnings Growth (YoY)
-18.2%
Share & Embed Analysis
Last updated: August 24, 2026 1:32 PM ET
Data refreshes hourly during market hours. Next update: 2:32 PM
Data refreshes hourly during market hours. Next update: 2:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QURE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Jeannette Potts
SELL
3412 shares
2026-03-04
Matthew C Kapusta
SELL
14581 shares
2026-03-04
Walid Abi-Saab
SELL
808 shares
2026-03-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
Advanced QURE Option Strategies
Professional options setups generated by AI based on today's QURE price and gamma walls.
